BioMarin Pharmaceutical (BMRN) free cash flow

Free cash flow · fiscal 2025
$717.02M

BioMarin Pharmaceutical (BMRN) generated free cash flow of $717.02M in fiscal 2025 (the year ended December 31, 2025). That is 50.8% higher than the $475.42M of fiscal 2024. Figures as of 18 Nov 2026, 12:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$717.02M
Change on fiscal 2024
+50.8%
Highest on record
$717.02Mfiscal 2025
Lowest on record
-$447.15Mfiscal 2015
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BioMarin Pharmaceutical free cash flow, in more detail

Across the 18 fiscal years on record (2008–2025), the highest was $717.02M in fiscal 2025 and the lowest -$447.15M in fiscal 2015.

History · 18 fiscal years

Free cash flow by fiscal year

BioMarin Pharmaceutical free cash flow, year by year

BioMarin Pharmaceutical (BMRN) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$717.02M 50.8% up
2024$475.42M 820.5% up
2023$51.65M 16.4% up
2022$44.36M 78.8% down
2021$208.96M—
2020-$28.95M—
2019-$96.76M—
2018-$124.41M—
2017-$207.98M—
2016-$376.22M—
2015-$447.15M—
2014-$187.48M—
2013-$124.83M—
2012-$26.96M—
2011-$54.80M—
2010-$30.72M—
2009-$2.07M—
2008-$65.54M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of BioMarin Pharmaceutical and comparable companies
CompanyFree cash flowFiscal year
Universal Health Services UHS$824.55M2025
Repligen RGEN$91.69M2025
Bio-Techne TECH$263.22M2026
BioMarin Pharmaceutical BMRN$717.02M2025
Avantor AVTR$495.00M2025
Ensign Group ENSG$370.71M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BMRN

BioMarin Pharmaceutical, figure by figure

BioMarin Pharmaceutical (BMRN) overview: price, valuation and scorecardAll health care companies by market value

BioMarin Pharmaceutical free cash flow: questions and answers

What is BioMarin Pharmaceutical's free cash flow?

BioMarin Pharmaceutical (BMRN) generated free cash flow of $717.02M in fiscal 2025 (the year ended December 31, 2025). That is 50.8% higher than the $475.42M of fiscal 2024.

What are the highest and lowest free cash flow figures on record for BioMarin Pharmaceutical?

Across the 18 fiscal years on record (2008–2025), the highest was $717.02M in fiscal 2025 and the lowest -$447.15M in fiscal 2015.

How is BioMarin Pharmaceutical's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For BioMarin Pharmaceutical it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BioMarin Pharmaceutical (BMRN) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/BMRN/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.